Abstract:Immune checkpoint inhibitors are the most striking innovation in the clinical development of immunotherapy. Monoclonal antibodies (mAbs) restore and augment the antitumor immune activities of cytotoxic T cells by mainly blocking immune checkpoint molecules on T cells or their ligands on antigen-presenting and tumor cells. Based on preclinical data, many clinical trials have demonstrated the acceptable safety profiles and efficacies of mAb in various cancers. The A first-in-class approved immune checkpoint inhibitor is ipilimumab, which is a fully humanized mAb that blocks the immunosuppressive signal by cytotoxic T-lymphocyte antigen 4. In 2011, the US Food and Drug Administration approved the use of ipilimumab for the treatment of advanced metastatic melanoma. Then, nivolumab, which is a humanized mAb that blocks programmed death-1 (PD-1), was approved for use in the treatment of advanced melanoma in 2014 and of advanced non-small-cell lung carcinoma (NSCLC) in 2015 in Japan. Pembrolizumab, which is another anti-PD-1 antibody, was approved for use in the treatment of advanced melanoma and advanced NSCLC as the first-line therapy in 2016 in Japan. Thereafter, nivolumab was also approved for use in the treatment of advanced renal cell cancer in August 2016, of Hodgkin's lymphoma in December 2016, and of head and neck cancer in March 2017 in Japan. Moreover, phase III trials of anti-PD-1 mAb and anti-PD-ligand 1 mAb for use in the treatment of cancers, such as gastric, ovarian, bladder, and esophageal cancers, are ongoing. Several clinical trials have investigated new agents, alone and in combination, for use in the treatment of various cancers. Current advances in tumor immunology have unveiled the importance of immunosuppressive cells, such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, especially in a tumor microenvironment (TME). Some data from basic research in mouse models and the immunomonitoring of cancer patients suggest that the inhibition of immunosuppressive cells and the cytokines related to them activate and infiltrate cytotoxic T cells and in TME, which could be one of the next combination strategies. The current clinical development of, translational research on, and future challenges in utilizing immune checkpoint inhibitors are described.

[Immune-checkpoints: the new anti-cancer immunotherapies]

Immune Checkpoints in Cancers: From Signaling to the Clinic

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune checkpoint inhibitors: breakthroughs in cancer treatment

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Immune checkpoint: The novel target for antitumor therapy

The future of immune checkpoint therapy

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

[Development of immune checkpoint inhibitors]

Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy

Emerging immune checkpoints for cancer therapy

Small Molecule- and Peptide-Based Approaches

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

Immune checkpoint inhibitors: recent progress and potential biomarkers

New Immunotherapy and Lung Cancer

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations